A Comparative Study on the Effect of BCG-PSN and Thymopeptides on T-lymphocyte Subsets of Normal and Immunosuppressed Mice

To compare the effects of polysaccharide nucleic acid fraction of bacillus calmette guerin (BCG PSN) and thymopeptides on T lymphocytes of normal and immunosuppressed mice, CD4 + and CD8 + T lymphocyte subsets of single nucleic cell in thymus, spleen and peripheral blood were detected successively by flow cytometry after application of BCG PSN and thymopeptides. Meanwhile, CD4 +/CD8 + ratio was also calculated. The results showed that both BCG PSN and thymopeptides could decrease the proportion of CD4 + CD8 + T lymphocyte subsets in the thymus, at the same time increase CD4 + T lymphocyte, CD8 +T lymphocyte proportion in the three tissues. The fluctuation in amplitude was greater in thymopeptides group than that in BCG PSN group. It is concluded that acting location of thymopeptides is in thymus, its stimulating action is stronger than that of BCG PSN, while BCG PSN not only accelerates the differentiation in thymus, but also has some direct stimulation to peripheral CD4 +T lymphocytes, and can maintain CD4 +/CD8 + ratio within normal range. So, BCG PSN is safer.

Mixed nanomicelles loaded with thymopeptides-sodium deoxycholate/phospholipid improve drug absorption

AIM: To improve the absorption of thymopeptides(TH) by preparing sodium deoxycholate/phospholipid-mixed nanomicelles(SDC/PL-MMs). METHODS: TH-SDC/PL-MMs were prepared by a film dispersion method, and then evaluated using photon correlation spectroscopy(PCS), zeta potential measurement, as well as their physical stability after storage for several days. Furthermore, in situ intestinal single-pass perfusion experiments and pharmacodynamics in immunodeficient mice were performed to make a comparison with TH powders and the control drug in absorption properties. RESULTS: A narrow size distribution of nanomicelles, with a mean particle size of(149 ± 8.32) nm and a zeta potential of(-31.05 ± 2.52) mV, was obtained. The in situ intestine perfusion experiments demonstrated a significant advantage in absorption characteristics for TH compared to the other formulations, and oral administration of TH-SDC/PL-MMs potentiated an equivalent effect with i.h. TH in pharmacodynamic studies in immunodeficient mice. CONCLUSIONS: TH-SDC/PL-MMs prepared by a film dispersion method are able to improve the absorption of TH. SDC/PL-MMs might be a good approach for the more effective delivery of drugs like TH.

Effect of Thymosin Injection combined with entecavir therapy on the viral load, liver fibrosis and immune response of patients with compensated liver cirrhosis

Objective: To study the effect of Thymosin Injection combined with entecavir therapy on the viral load, liver fibrosis and immune response of patients with compensated liver cirrhosis. Methods: Patients who were diagnosed with chronic hepatitis b complicated by compensated liver cirrhosis in our hospital between March 2015 and January 2017 were selected and randomly divided into two groups, observation group received Thymosin Injection combined with entecavir therapy, and control group received entecavir therapy. The viral load, liver function injury indexes, liver fibrosis indexes, immune cytokines and immune cell apoptosis molecules were measured 24 weeks after treatment. Results: 24 weeks after treatment, HBV-DNA copy number in peripheral blood as well as ALT, AST, TBIL, HA, PC-III, LN, C-IV, IL-4, IL-10, TGF-β1, IL-17 and IL-22 levels in serum of observation group was significantly lower than those of control group, and peripheral blood FAS, CYCS, CASP8, CASP9 and CASP3 mRNA expression were significantly lower than those of control group. Conclusion:Thymosin Injection combined with entecavir therapy can reduce viral load, improve liver function, inhibit liver fibrosis and regulate immune function in patients with compensated liver cirrhosis.